new approaches for an integrated nonclinical-clinical qt/proarrhythmic risk assessment (1 of 2)
Published 3 years ago • 8.3K plays • Length 2:19:09Download video MP4
Download video MP3
Similar videos
-
2:02:52
new approaches for an integrated nonclinical-clinical qt/proarrhythmic risk assessment (2 of 2)
-
5:44
moving new science into the regulatory review process: focus on cardiac safety of new drugs
-
52:11
overview: clinical pharmacology considerations for food effect studies
-
52:08
plenary: regulatory research at fda (2/14) redi 2017
-
25:02
what does the fda say about digital pathology for nonclinical toxicology studies?
-
40:26
benefit-risk considerations during drug product development (8of14) redi 2018
-
1:13:12
us-canada regional ich consultation – part 2
-
39:41
referencing approved drug products in anda submissions
-
41:00
fda regulatory requirements for clinical investigators and case examples (9of14) redi 2018
-
1:10:40
bimo, rems, and pade inspection readiness (3of3) jun. 19, 2018
-
26:33
media call: second covid-19 vaccine – 12/18/2020
-
0:38
initial assessment and referral (iar) tool for mental health.
-
7:02
keynote - bioanalysis 2020
-
1:29:34
qms framework: best practices for implementation of risk management in clinical development
-
28:20
the patent information dispute process
-
56:35
send for cber, what you need to know
-
17:07
risk management for medical devices and iso 14971 - online introductory course
-
3:42
case 4: assessing risk for transformation to aml
-
52:59
caroline hurley webinar risk based monitoring and the introduction of the new ich-gcp guidelines